JP5785077B2 - 崩壊温度より高温での凍結乾燥 - Google Patents

崩壊温度より高温での凍結乾燥 Download PDF

Info

Publication number
JP5785077B2
JP5785077B2 JP2011522218A JP2011522218A JP5785077B2 JP 5785077 B2 JP5785077 B2 JP 5785077B2 JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011522218 A JP2011522218 A JP 2011522218A JP 5785077 B2 JP5785077 B2 JP 5785077B2
Authority
JP
Japan
Prior art keywords
temperature
freeze
collapse
less
primary drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011522218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530524A (ja
JP2011530524A5 (https=
Inventor
チェサロヴ セルゲイ
チェサロヴ セルゲイ
デクソン ダン
デクソン ダン
ワーン ニコラス
ワーン ニコラス
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41401614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5785077(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2011530524A publication Critical patent/JP2011530524A/ja
Publication of JP2011530524A5 publication Critical patent/JP2011530524A5/ja
Application granted granted Critical
Publication of JP5785077B2 publication Critical patent/JP5785077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011522218A 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥 Active JP5785077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642608P 2008-08-05 2008-08-05
US61/086,426 2008-08-05
PCT/US2009/052852 WO2010017296A1 (en) 2008-08-05 2009-08-05 Lyophilization above collapse

Publications (3)

Publication Number Publication Date
JP2011530524A JP2011530524A (ja) 2011-12-22
JP2011530524A5 JP2011530524A5 (https=) 2012-09-13
JP5785077B2 true JP5785077B2 (ja) 2015-09-24

Family

ID=41401614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522218A Active JP5785077B2 (ja) 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥

Country Status (6)

Country Link
US (1) US9884019B2 (https=)
EP (2) EP2323629B1 (https=)
JP (1) JP5785077B2 (https=)
CA (1) CA2729972C (https=)
ES (2) ES2755029T3 (https=)
WO (1) WO2010017296A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042408A2 (en) * 2006-10-03 2008-04-10 Wyeth Lyophilization methods and apparatuses
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にgdf−5を含むタンパク質製剤
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3323410A1 (en) * 2016-11-22 2018-05-23 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Pharmaceutical parenteral formulation containing carglumic acid
CN107543373B (zh) * 2017-09-06 2019-04-26 华派生物工程集团有限公司 一种活疫苗的冷冻干燥方法
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
CN109369821B (zh) * 2018-11-28 2021-12-14 四川恒通动保生物科技有限公司 一种黄芪多糖的高效提取制备方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
BR112022015272A2 (pt) 2020-02-04 2022-09-20 Regeneron Pharma Teor de umidade residual alvo para produto de fármaco liofilizado

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
BR9507909A (pt) * 1994-06-03 1997-08-12 Procter & Gamble Formas de dosagem de rápida dissolução
RU2111426C1 (ru) 1995-11-03 1998-05-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ лиофильной сушки биопрепарата
DE69928500T2 (de) 1998-03-03 2006-08-03 Eli Lilly And Co., Indianapolis Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1750760B1 (en) * 2004-06-02 2017-06-28 Universal Stabilization Technologies, Inc. Preservation by vaporization
CA2576549C (en) * 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
WO2006081320A2 (en) * 2005-01-27 2006-08-03 Human Genome Sciences, Inc. Pharmaceutical formulation
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
JP2011526356A (ja) 2008-06-26 2011-10-06 ワイス・エルエルシー 凍結乾燥サイクルのロバスト性(robustness)方策
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse

Also Published As

Publication number Publication date
CA2729972C (en) 2018-11-20
EP3572073C0 (en) 2023-12-20
JP2011530524A (ja) 2011-12-22
EP2323629A1 (en) 2011-05-25
EP3572073B1 (en) 2023-12-20
WO2010017296A1 (en) 2010-02-11
ES2968301T3 (es) 2024-05-08
CA2729972A1 (en) 2010-02-11
ES2755029T3 (es) 2020-04-21
EP2323629B1 (en) 2019-10-09
EP3572073A1 (en) 2019-11-27
US20100041870A1 (en) 2010-02-18
US9884019B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
JP5785077B2 (ja) 崩壊温度より高温での凍結乾燥
Pardeshi et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review
CN101855336B (zh) 含艰难梭菌类毒素a和b的药物组合物
ES2434840T3 (es) Formulación de proteína liofilizada isotónica estable
US11241498B2 (en) Room temperature stable lyophilized protein
JP7264986B2 (ja) 抗Her2抗体薬物コンジュゲートの製剤
CN101277611A (zh) 药物制剂
KR20120027031A (ko) 소형 모듈 면역제약용 동결건조 제제
US11713922B2 (en) Target residual moisture content for lyophilized drug product
CA2721019A1 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
JP2012121894A (ja) Il−1アンタゴニスト製剤
KR20090007588A (ko) 니코틴-담체 백신 제제
JP2011530524A5 (https=)
KR20210078514A (ko) 항-rsv 항체의 제제 및 그의 사용 방법
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
KR20260025359A (ko) 다클론 IgM을 포함하는 동결건조 조성물을 생산하는 방법 및 수득된 조성물
KR20240099278A (ko) 에프룩시페르민의 제약 조성물
CN113699120A (zh) 耐热保护剂及其应用以及可室温保存的活病毒的保存方法
HK40087140A (zh) 组织纤溶酶原激活剂制剂
WO2024172859A1 (en) Peptide formulations
TW202604569A (zh) 薩西土珠單抗戈維特坎配方及製造方法
KR20260051486A (ko) 콜라게나제 제형 및 이의 제조 방법
HK1230484A1 (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
HK1147285A (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150723

R150 Certificate of patent or registration of utility model

Ref document number: 5785077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250